See what people are recommending in #Maryland
It's a new age in treatments for Alzheimer's disease, with two new drugs on the market that slow the disease. The Food and Drug Administration in 2021 approved aducanumab, which goes by the brand name Aduhelm, and in July, approved lecanemab, which goes by the brand name Leqembi. "Both of these medications are monoclonal antibodies, which means they attack beta-amyloid plaques. Amyloid is a hallmark protein in the disease," said Megeen White.